#United States #Allentown #Glenmark Pharmaceuticals #U.S. Distribution

Glenmark Pharmaceuticals Expands U.S. Operations

Glenmark Pharmaceuticals Inc. USA has unveiled its new distribution center located in Allentown, Pennsylvania, a strategic move to enhance its operational capabilities and supply-chain structure in the United States. This significant milestone marks a notable expansion for Glenmark, which has been serving patients in the U.S. for over twenty years.

The inauguration was celebrated with a festive ribbon-cutting ceremony attended by various dignitaries, including Allentown Mayor Matt Tuerk and Pennsylvania State legislators, who recognized the potential of this facility to create jobs and ensure a steady supply of medications to American patients. Glenmark's new distribution center is not only the largest of its kind for the company in North America but also serves as its sole distribution hub in the country.

Located on a sprawling 6.5-acre campus, the facility spans approximately 160,000 square feet. Approximately 45 employees will ensure smooth operations, supporting the distribution of both prescription and over-the-counter medicines across 321 locations in 43 states. Marc Kikuchi, President and Business Head of North America at Glenmark, expressed pride in the investment into the Lehigh Valley, citing the area's strong community and skilled workforce as key factors in the decision to establish operations there.

This distribution hub will serve pivotal roles in maintaining efficient supply chains, especially as the center complies with strict Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) regulations. The facility is designed to handle diverse storage requirements, including controlled room temperature and refrigerated cold-chain environments, ensuring that all products maintain their efficacy and safety standards during transit.

To date, the Allentown center has shipped over 61 million units across the United States and reflects Glenmark's commitment to bolstering the American pharmaceutical infrastructure. The company has invested nearly $1 billion in its U.S. operations, with about $400 million allocated for its FDA-approved manufacturing facility located in Monroe, North Carolina. Glenmark's portfolio features over 229 FDA-authorized products, which play a crucial role in providing approximately 90 million prescriptions annually.

Political leaders hailed the new facility as a catalyst for economic growth and sustainability in the region. Congressman Ryan Mackenzie applauded Glenmark's investment, highlighting its significance in creating jobs and ensuring reliable access to medications for local patients. Mayor Tuerk remarked on the positive impact this facility would have on the Allentown economy and job market.

Safety and sustainability are integral components of the daily operations at the facility. Employees are trained thoroughly on emergency procedures, including evacuations and medical emergency responses. Additionally, the facility implements energy-efficient practices, waste reduction initiatives, recycling programs, and optimized delivery routes to minimize environmental impacts.

Glenmark Pharmaceuticals' Allentown distribution center adds to its established presence, which includes a corporate headquarters in Elmwood Park, New Jersey; a manufacturing facility in Monroe, North Carolina; and a biotechnology subsidiary, Ichnos Glenmark Innovation, located in New York. The interconnectedness of these operations strengthens Glenmark's position as a leader in innovation, manufacturing, and distribution within the American pharmaceutical landscape.

Overall, Glenmark's expansion not only amplifies its operational capacity but also exemplifies its commitment to serving patients, customers, and partners across the U.S., reinforcing the importance of a robust domestic pharmaceutical supply chain.